Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB): Price and Financial Metrics

Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB): $2.18

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

TRIB Price/Volume Stats

Current price $2.18 52-week high $6.20
Prev. close $2.18 52-week low $1.85
Day low $2.18 Volume 695
Day high $2.25 Avg. volume 133,850
50-day MA $2.38 Dividend yield N/A
200-day MA $3.33 Market Cap 16.62M

TRIB Stock Price Chart Interactive Chart >


Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB) Company Bio


Trinity Biotech plc develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The company was founded in 1992 and is based in Bray, Ireland.


TRIB Latest News Stream


Event/Time News Detail
Loading, please wait...

TRIB Latest Social Stream


Loading social stream, please wait...

View Full TRIB Social Stream

Latest TRIB News From Around the Web

Below are the latest news stories about TRINITY BIOTECH PLC that investors may wish to consider to help them evaluate TRIB as an investment opportunity.

Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya

DUBLIN, Ireland, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces it has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV. The Kenyan HIV screening programme is one of the largest in Africa, with an estimated 10 million HIV screening tests performed annually. The Company has begun commercial

Yahoo | December 27, 2023

Trinity Biotech Announces Management Changes

John Gillard Named Chief Executive OfficerDes Fitzgerald Named Interim Chief Financial Officer DUBLIN, Ireland, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the promotion of John Gillard, our Chief Financial Officer, to President and Chief Executive Officer, effective immediately. Des Fitzgerald, who has served as Director of

Yahoo | December 18, 2023

Trinity Biotech plc (NASDAQ:TRIB) Held Back By Insufficient Growth Even After Shares Climb 31%

Those holding Trinity Biotech plc ( NASDAQ:TRIB ) shares would be relieved that the share price has rebounded 31% in...

Yahoo | December 18, 2023

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

DUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that on November 21, 2023 the Company received notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the minimum market value of publicly held shares ("MVPHS") requirement set forth in the Nasdaq Listing Rules.

Yahoo | November 28, 2023

Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health

DUBLIN, Ireland, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, welcomes the recent decision by the High Court of Kenya. The court has struck out both the interim application and the entire lawsuit filed by Gamma Zenith Kenya Limited against Trinity Biotech, Radiance Pharmaceutical, the Kenyan Ministry of Health, and the Kenyan Attorney General

Yahoo | October 10, 2023

Read More 'TRIB' Stories Here

TRIB Price Returns

1-mo -26.10%
3-mo -14.51%
6-mo -39.44%
1-year -57.46%
3-year -92.09%
5-year -85.94%
YTD 1.63%
2023 -56.67%
2022 -30.77%
2021 -62.47%
2020 268.69%
2019 -54.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!